In the literature dropout depends on multiple factors, including wait list time, HCC characteristics (solitary tumor greater than 3 cm, two or three tumor nodules), elevated baseline AFP level (≥100 ng/ml), increased AFP concentration, Child-Pugh status, MELD score at listing, use of bridge therapy and response to bridge therapy (20–24). The gene discussed is AFP; the disease is neoplasm.